The Rest Is Money 231. Can The NHS Afford The UK-US Pharma Deal?
30 snips
Dec 4, 2025 Lord Patrick Vallance, a leading physician and former UK Chief Scientific Adviser, discusses the implications of the UK-US pharma deal on the NHS. He explains why the NHS is paying higher prices for new medicines and the potential of UK life sciences to attract investment. Vallance emphasizes the importance of scaling startups, the innovative power of British tech, and discusses the need for a shift in government procurement strategies. He also reflects on important pandemic lessons and the role of in-person connections in business.
AI Snips
Chapters
Transcript
Episode notes
Plan For Higher NHS Drug Spending
- Expect NHS medicines spending to rise from about 10% back toward 12% of the health budget over time.
- Policymakers should treat this as a reallocation toward modern, often curative, medicines that can save future acute care costs.
Rebate Cap Cuts Increase NHS Net Drug Costs
- The drug-company rebate cap will fall from an unexpected 23% down to 15%, reducing NHS rebates and raising net costs.
- Vallance estimates the overall increase could be in the low billions annually as new medicines ramp up.
Big Biotech Investments Illustrate UK Appeal
- Major life‑science firms and new entrants like Moderna and BioNTech have made large UK investments.
- Vallance uses these examples to show the UK's continued attractiveness for research and manufacturing.